Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
6
×
boston blog main
6
×
life sciences
national blog main
boston top stories
national top stories
new york blog main
new york top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
biogen
clinical trials
crispr
deals
editas medicine
gene editing
gilead sciences
indiana blog main
indiana top stories
novartis
allergan
alzheimer's disease
amgen
What
ceo
6
×
bio
roundup
acquisitions
crispr
biggest
daniel
drug
editas
gilead
katrine
medicine
medicines
moves
o’day
sciences
week
aims
albert
allergan
announced
backed
big
blessing
bosley
bosley's
bosley’s
bourla
bridge
bucks
build
buy
cas
cause
check
clinical
collabs
company
company’s
covid
Language
unset
unknown
Current search:
biotech
×
ceo
×
" boston blog main "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial